paclitaxel cationic liposome + oxaliplatin + capecitabine + bevacizumab

This combination consists of four agents: paclitaxel cationic liposome, oxaliplatin, capecitabine, and bevacizumab. **Paclitaxel cationic liposome** is a nanoparticle formulation of paclitaxel encapsulated in cationic liposomes to enhance drug delivery, tumor accumulation, and reduce toxicity, with demonstrated preclinical and clinical evidence primarily in solid tumors[2][5][8]. **Oxaliplatin** is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit replication and transcription, leading to cell death. **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), which interferes with DNA synthesis, and is used for various gastrointestinal and breast cancers. **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting tumor angiogenesis[3][6][9]. The combination is designed as a multi-agent chemotherapy plus angiogenesis inhibition, which may be used in advanced solid tumors such as gastrointestinal cancers, small bowel adenocarcinoma, ampullary adenocarcinoma, and possibly other tumor types, but as of yet is not established as a standard therapy for any single indication[2][7].